What Does ABBV-744 in clinical trials for non-small cell lung cancer (NSCLC) Mean?
In Segment C, members will obtain ABBV-744 and oral navitoclax. In Section D, participants will obtain ABBV-744 and ruxolitinib. Members will receive treatment till sickness progression or even the members are unable to tolerate the study drugs.Total, our recent work highlights the potential utilization of ARV-825 in combination with TAM. When ABBV